Skip to main content
For Healthcare Professionals

GLYXAMBI®

Overview

For adults with type 2 diabetes mellitus, GLYXAMBI® can improve glycemic control along with diet and exercise.1

Product overview

GLYXAMBI® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effect of GLYXAMBI® to reduce cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease has not established yet. GLYXAMBI® is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. GLYXAMBI® has not been studied in patients with a history of pancreatitis, and it is unknown if GLYXAMBI® would increase the risk of developing pancreatitis in these patients.1

Product key facts

product_key1

Indication

GLYXAMBI® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who did not reach optimal glycemic control under metformin and empagliflozin or linagliptin, or those who are already on empagliflozin and linagliptin combination therapy.1

product_key6

Active ingredients

A combination of empagliflozin and linagliptin.1

product_Key7

Legal category

Prescription only medicine.1

product_key3

Dosage form and drug content

Film-coated tablets:
Empagliflozin 25 mg and linagliptin 5 mg.1

product_key4

Administration form

Oral administration.1

product_key1

Pack sizes

One box contains 2-1,000 tablets in aluminum foil package.1

TAIWAN NHIA REIMBURSEMENT CRITERIA2

According to the reimbursement criteria from Taiwan NHIA, GLYXAMBI® can only be reimbursed under following conditions:

  • When used in patients with type 2 diabetes mellitus whose HbA1c 7.5% despite treatment with maximum tolerated dose of metformin, and concurrent treatment with either JARDIANCE® or TRAJENTA® for at least 6 months
  • Do not exceed one tablet per day

Footnotes:

  • DPP-4, dipeptidyl peptidase-4; HbA1c, glycated hemoglobin; NHIA, National Health Insurance Administration; SGLT-2, sodium-glucose co-transporter 2.

References:

  1. GLYXAMBI® approved package insert. Updated in May 2020. Approved in September 2020.

  2. Reimbursement criteria from National Health Insurance for Hormones drugs affecting hormonal mechanism. https://www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC82MTMzL2NoYXA1XzExMDA2LnBkZg%3d%3d&n=Y2hhcDVfMTEwMDYucGRm&ico%20=.pdf.Accessed 02 Aug 2021.

Related News

Reporting adverse events

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.